Page 16 - கனடா தொழில்துறை ஆராய்ச்சி உதவி ப்ரோக்ர்யாம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Qu Biologics Receives Funding for COVID-19 Prevention/Treatment Research with Qu s Novel Immunotherapy Platform – IT Business Net
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
Qu Biologics Receives Funding for COVID-19 Prevention/Treatment Research with Qu s Novel Immunotherapy Platform - Press Release
digitaljournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from digitaljournal.com Daily Mail and Mail on Sunday newspapers.
MIL-OSI Canada: National Research Council of Canada supports development of 4 COVID-19 therapeutic candidates
foreignaffairs.co.nz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from foreignaffairs.co.nz Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
MONCTON, NB, Dec. 17, 2020 /CNW/ - Soricimed Biopharma Inc., ( Soricimed ), a privately-held, science-based, clinical stage company focused on the development and commercialization of first-in-class targeted cancer therapeutics, today announced that it will investigate the potential therapeutic role its cancer drug candidate, SOR-C13, can play in helping relieve or prevent severe immune response to the SARS CoV-2 virus.
Soricimed is currently developing SOR-C13, a TRPV6 calcium channel inhibitor, for the treatment of solid-tumour cancers. SOR-C13 is designed to decrease calcium concentrations inside cancer cells to inhibit calcium-dependent cancer cell proliferation and induce the death of tumour cells overexpressing TRPV6.